Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-022 maintenance sacituzumab tirumotecan with or without bevacizumab versus standard of care in platinum-sensitive recurrent ovarian cancer
MOH_2025-10-20_014386Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Merck & Co. Started Sep 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2025-10-20_014386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-10-20_014386.